Marvin Fritzler

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7972159/publications.pdf

Version: 2024-02-01

344 papers	22,190 citations	15466 65 h-index	11581 135 g-index
350 all docs	350 docs citations	350 times ranked	14348 citing authors

#	Article	IF	Citations
1	Stress granules and processing bodies are dynamically linked sites of mRNP remodeling. Journal of Cell Biology, 2005, 169, 871-884.	2.3	1,237
2	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1400-1412.	2.9	1,098
3	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 1151-1159.	0.5	759
4	Range of antinuclear antibodies in â€œhealthyâ€•individuals. Arthritis and Rheumatism, 1997, 40, 1601-1611.	6.7	758
5	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respiratory Medicine,the, 2016, 4, 708-719.	5.2	754
6	Autoantibody to centromere (kinetochore) in scleroderma sera.. Proceedings of the National Academy of Sciences of the United States of America, 1980, 77, 1627-1631.	3.3	700
7	Autoantibody to a nuclear antigen in proliferating cells. Journal of Immunology, 1978, 121, 2228-34.	0.4	586
8	Autoantibody explosion in systemic lupus erythematosus: More than 100 different antibodies found in SLE patients. Seminars in Arthritis and Rheumatism, 2004, 34, 501-537.	1.6	549
9	Diversity of antinuclear antibodies in progressive systemic sclerosis. Arthritis and Rheumatism, 1980, 23, 617-625.	6.7	511
10	Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: A twentyâ€year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis and Rheumatism, 2008, 58, 3902-3912.	6.7	507
11	International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Annals of the Rheumatic Diseases, 2014, 73, 17-23.	0.5	471
12	Disruption of GW bodies impairs mammalian RNA interference. Nature Cell Biology, 2005, 7, 1267-1274.	4.6	418
13	The CREST syndrome: A distinct serologic entity with anticentromere antibodies. American Journal of Medicine, 1980, 69, 520-526.	0.6	365
14	A Phosphorylated Cytoplasmic Autoantigen, GW182, Associates with a Unique Population of Human mRNAs within Novel Cytoplasmic Speckles. Molecular Biology of the Cell, 2002, 13, 1338-1351.	0.9	323
15	Antibodies to Histones in Drug-Induced and Idiopathic Lupus Erythematosus. Journal of Clinical Investigation, 1978, 62, 560-567.	3.9	275
16	Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014â€“2015. Frontiers in Immunology, 2015, 6, 412.	2.2	270
17	Idiopathic inflammatory myopathies and the anti-synthetase syndrome: A comprehensive review. Autoimmunity Reviews, 2014, 13, 367-371.	2.5	233
18	The GW182 protein colocalizes with mRNA degradation associated proteins hDcp1 and hLSm4 in cytoplasmic GW bodies. Rna, 2003, 9, 1171-1173.	1.6	231

#	Article	IF	Citations
19	Systemic sclerosis in 3 US ethnic groups: A comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Seminars in Arthritis and Rheumatism, 2001, 30, 332-346.	1.6	228
20	Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Annals of the Rheumatic Diseases, 2019, 78, 879-889.	0.5	217
21	CENP-F is a ca 400 kDa kinetochore protein that exhibits a cell-cycle dependent localization. Cytoskeleton, 1993, 26, 214-226.	4.4	196
22	Autoantibodies in systemic sclerosis. Autoimmunity Reviews, 2013, 12, 340-354.	2.5	192
23	GW182 is critical for the stability of GW bodies expressed during the cell cycle and cell proliferation. Journal of Cell Science, 2004, 117, 5567-5578.	1.2	186
24	Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Research and Therapy, 2007, 9, R78.	1.6	167
25	A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities: I. Precision, sensitivity, and specificity. Arthritis and Rheumatism, 1999, 42, 455-464.	6.7	163
26	Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis and Rheumatism, 1996, 39, 1151-1160.	6.7	159
27	Molecular cloning of a novel 97-kd Golgi complex autoantigen associated with SjÃ¶gren's syndrome. Arthritis and Rheumatism, 1997, 40, 1693-1702.	6.7	157
28	Antinuclear, anticytoplasmic, and anti-Sjogren's Syndrome antigen A (SS-A/Ro) antibodies in female blood donors. Clinical Immunology and Immunopathology, 1985, 36, 120-128.	2.1	154
29	Current Concepts and Future Directions for the Assessment of Autoantibodies to Cellular Antigens Referred to as Anti-Nuclear Antibodies. Journal of Immunology Research, 2014, 2014, 1-18.	0.9	148
30	Molecular characterization of two human autoantigens: unique cDNAs encoding 95- and 160-kD proteins of a putative family in the Golgi complex.. Journal of Experimental Medicine, 1993, 178, 49-62.	4.2	141
31	Anti-DFS70/LEDGF Antibodies Are More Prevalent in Healthy Individuals Compared to Patients with Systemic Autoimmune Rheumatic Diseases. Journal of Rheumatology, 2012, 39, 2104-2110.	1.0	136
32	Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19. Nature Medicine, 2022, 28, 201-211.	15.2	132
33	The C-terminal half of human Ago2 binds to multiple GW-rich regions of GW182 and requires GW182 to mediate silencing. Rna, 2009, 15, 804-813.	1.6	130
34	International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. Autoimmunity Highlights, 2016, 7, 1.	3.9	116
35	The role of GW/P-bodies in RNA processing and silencing. Journal of Cell Science, 2007, 120, 1317-1323.	1.2	112
36	Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Research and Therapy, 2012, 14, R50.	1.6	110

#	Article	IF	Citations
37	Formation of GW bodies is a consequence of microRNA genesis. EMBO Reports, 2006, 7, 904-910.	2.0	109
38	Anticentromere antibodies in primary biliary cirrhosis. Arthritis and Rheumatism, 1983, 26, 914-917.	6.7	105
39	Epitope specificity and significance in systemic autoimmune diseases. Annals of the New York Academy of Sciences, 2010, 1183, 267-287.	1.8	105
40	Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. Autoimmunity Reviews, 2016, 15, 983-993.	2.5	105
41	Primary Biliary Cirrhosis (PBC), PBC Autoantibodies, and Hepatic Parameter Abnormalities in a Large Population of Systemic Sclerosis Patients. Journal of Rheumatology, 2009, 36, 2250-2256.	1.0	101
42	Primary ciliogenesis defects are associated with human astrocytoma/glioblastoma cells. BMC Cancer, 2009, 9, 448.	1.1	100
43	Molecular Characterization of Golgin-245, a Novel Golgi Complex Protein Containing a Granin Signature. Journal of Biological Chemistry, 1995, 270, 31262-31268.	1.6	99
44	Autoimmune targeting of key components of RNA interference. Arthritis Research and Therapy, 2006, 8, R87.	1.6	98
45	Autoantibodies to protein transport and messenger RNA processing pathways: endosomes, lysosomes, Golgi complex, proteasomes, assemblyosomes, exosomes, and GW bodies. Clinical Immunology, 2004, 110, 30-44.	1.4	96
46	Clinical and serological features of patients with autoantibodies to GW/P bodies. Clinical Immunology, 2007, 125, 247-256.	1.4	95
47	Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmunity Reviews, 2012, 11, 642-645.	2.5	92
48	The antinuclear antibody test: Last or lasting gasp?. Arthritis and Rheumatism, 2011, 63, 19-22.	6.7	90
49	Clinical and Serologic Correlates of Antiâ€PM/Scl Antibodies in Systemic Sclerosis: A Multicenter Study of 763 Patients. Arthritis and Rheumatology, 2014, 66, 1608-1615.	2.9	90
50	Autoantibodies in Systemic Sclerosis: Unanswered Questions. Frontiers in Immunology, 2015, 6, 167.	2.2	90
51	Autoantibodies to a group of centrosomal proteins in human autoimmune sera reactive with the centrosome. Arthritis and Rheumatism, 1998, 41, 551-558.	6.7	86
52	A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clinical Rheumatology, 2007, 27, 77-83.	1.0	84
53	Cutting edge diagnostics in rheumatology: The role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology. Arthritis and Rheumatism, 2004, 51, 291-298.	6.7	81
54	Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015. Lupus, 2016, 25, 797-804.	0.8	81

#	Article	IF	Citations
55	International Multicenter Evaluation of Autoantibodies to Ribosomal P Proteins. Vaccine Journal, 2006, 13, 77-83.	3.2	80
56	Detection of the argonaute protein Ago2 and microRNAs in the RNA induced silencing complex (RISC) using a monoclonal antibody. Journal of Immunological Methods, 2006, 317, 38-44.	0.6	79
57	2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmunity Reviews, 2020, 19, 102618.	2.5	79
58	The significance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding. Clinical and Experimental Medicine, 2016, 16, 273-293.	1.9	78
59	The Clinical Significance of the Dense Fine Speckled Immunofluorescence Pattern on HEp-2 Cells for the Diagnosis of Systemic Autoimmune Diseases. Clinical and Developmental Immunology, 2012, 2012, 1-6.	3.3	76
60	Autoantibodies 2015: From diagnostic biomarkers toward prediction, prognosis and prevention. Autoimmunity Reviews, 2015, 14, 555-563.	2.5	76
61	Advances and Applications of Multiplexed Diagnostic Technologies in Autoimmune Diseases. Lupus, 2006, 15, 422-427.	0.8	75
62	Cytoplasmic ribonucleoprotein (RNP) bodies and their relationship to GW/P bodies. International Journal of Biochemistry and Cell Biology, 2010, 42, 828-843.	1.2	75
63	Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies. Arthritis Research and Therapy, 2008, 10, R131.	1.6	74
64	Antinuclear Antibodyâ€“Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	1.5	70
65	Circulating Calprotectin as a Biomarker of COVID-19 Severity. Expert Review of Clinical Immunology, 2021, 17, 431-443.	1.3	70
66	Comparison between multiplex assays for autoantibody detection in systemic lupus erythematosus. Journal of Immunological Methods, 2010, 358, 75-80.	0.6	68
67	Choosing wisely: Review and commentary on anti-nuclear antibody (ANA) testing. Autoimmunity Reviews, 2016, 15, 272-280.	2.5	66
68	Clinical Phenotypes of Patients with Anti-DFS70/LEDGF Antibodies in a Routine ANA Referral Cohort. Clinical and Developmental Immunology, 2013, 2013, 1-8.	3.3	65
69	Clinical and Serological Features of Patients Referred through a Rheumatology Triage System because of Positive Antinuclear Antibodies. PLoS ONE, 2014, 9, e93812.	1.1	65
70	Autoantibodies in Pediatric Systemic Lupus Erythematosus: Ethnic Grouping, Cluster Analysis, and Clinical Correlations. Journal of Rheumatology, 2009, 36, 416-421.	1.0	64
71	The clinical utility of anti-double-stranded DNA antibodies and the challenges of their determination. Journal of Immunological Methods, 2018, 459, 11-19.	0.6	64
72	Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmunity Reviews, 2011, 10, 194-200.	2.5	63

#	Article	IF	Citations
73	Systemic Sclerosis Sine Scleroderma: A Multicenter Study of 1417 Subjects. Journal of Rheumatology, 2014, 41, 2179-2185.	1.0	63
74	Localized scleroderma progressing to systemic disease. case report and review of the literature. Arthritis and Rheumatism, 1993, 36, 410-415.	6.7	62
75	Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies. Arthritis Research, 2005, 7, R19.	2.0	62
76	A clinical approach to autoantibody testing in systemic autoimmune rheumatic disorders. Autoimmunity Reviews, 2007, 7, 77-84.	2.5	62
77	Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness. Expert Review of Clinical Immunology, 2019, 15, 241-250.	1.3	62
78	Characterization of the human autoimmune response to the major C-terminal epitope of the ribosomal P proteins. Journal of Molecular Medicine, 2003, 81, 194-204.	1.7	61
79	Clinical and serological associations of autoantibodies to GW bodies and a novel cytoplasmic autoantigen GW182. Journal of Molecular Medicine, 2003, 81, 811-818.	1.7	61
80	Update on autoantibodies in systemic sclerosis. Current Opinion in Rheumatology, 2007, 19, 580-591.	2.0	60
81	Challenges to the use of autoantibodies as predictors of disease onset, diagnosis and outcomes. Autoimmunity Reviews, 2008, 7, 616-620.	2.5	60
82	Antinuclear antibody-negative systemic sclerosis. Seminars in Arthritis and Rheumatism, 2015, 44, 680-686.	1.6	60
83	2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis Outperform the 1980 Criteria: Data From the Canadian Scleroderma Research Group. Arthritis Care and Research, 2015, 67, 582-587.	1.5	60
84	Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies. Autoimmunity Reviews, 2022, 21, 103012.	2.5	60
85	The use and abuse of commercial kits used to detect autoantibodies. Arthritis Research, 2003, 5, 192.	2.0	59
86	Identification of GW182 and its novel isoform TNGW1 as translational repressors in Ago2-mediated silencing. Journal of Cell Science, 2008, 121, 4134-4144.	1.2	59
87	Prevalence of systemic lupus erythematosus and systemic sclerosis in the First Nations population of Alberta, Canada. Arthritis Care and Research, 2012, 64, 138-143.	1.5	59
88	PR3-ANCA: A Promising Biomarker in Primary Sclerosing Cholangitis (PSC). PLoS ONE, 2014, 9, e112877.	1.1	57
89	Antiphospholipase A₂Receptor Autoantibodies: A Comparison of Three Different Immunoassays for the Diagnosis of Idiopathic Membranous Nephropathy. Journal of Immunology Research, 2014, 2014, 1-5.	0.9	57
90	Solid phase assays versus automated indirect immunofluorescence for detection of antinuclear antibodies. Autoimmunity Reviews, 2018, 17, 533-540.	2.5	57

#	Article	IF	Citations
91	Clinical features of patients with antibodies directed against proliferating cell nuclear antigen. Arthritis and Rheumatism, 1983, 26, 140-145.	6.7	56
92	Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blotting. Arthritis and Rheumatism, 1997, 40, 413-418.	6.7	56
93	The Frequency of Phospholipid Antibodies in an Unselected Stroke Population. Canadian Journal of Neurological Sciences, 1998, 25, 64-69.	0.3	56
94	Towards a better understanding of the clinical association of anti-DFS70 autoantibodies. Autoimmunity Reviews, 2016, 15, 198-201.	2.5	56
95	Recognition of the dense fine speckled (DFS) pattern remains challenging: results from an international internet-based survey. Autoimmunity Highlights, 2016, 7, 8.	3.9	55
96	Clinical Correlates of CENP-A and CENP-B Antibodies in a Large Cohort of Patients with Systemic Sclerosis. Journal of Rheumatology, 2012, 39, 787-794.	1.0	54
97	Evidence for Epigenetic Regulation of Gene Expression and Function in Chronic Experimental Diabetic Neuropathy. Journal of Neuropathology and Experimental Neurology, 2015, 74, 804-817.	0.9	54
98	The Emergence of Multiplexed Technologies as Diagnostic Platforms in Systemic Autoimmune Diseases. Current Medicinal Chemistry, 2006, 13, 2503-2512.	1.2	53
99	International consensus on antinuclear antibody patterns: definition of the AC-29 pattern associated with antibodies to DNA topoisomerase I. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1783-1788.	1.4	53
100	Calcinosis is associated with digital ischaemia in systemic sclerosisâ€"a longitudinal study. Rheumatology, 2016, 55, 2148-2155.	0.9	52
101	The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus, 2017, 26, 1051-1059.	0.8	52
102	AutoAbSC.Org â€" Autoantibody Standardization Committee in 2006. Autoimmunity Reviews, 2007, 6, 577-580.	2.5	51
103	Speckled pattern antinuclear antibodies resembling anticentromere antibodies. Arthritis and Rheumatism, 1984, 27, 92-96.	6.7	50
104	A review and meta-analysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus. Autoimmunity Reviews, 2020, 19, 102463.	2.5	50
105	Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA. Journal of Rheumatology, 2007, 34, 1528-34.	1.0	50
106	The spindle kinesin-like protein HsEg5 is an autoantigen in systemic lupus erythematosus. Arthritis and Rheumatism, 1996, 39, 1635-1642.	6.7	49
107	Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen. Arthritis Research, 2005, 7, R704.	2.0	49
108	GW Bodies, MicroRNAs and the Cell Cycle. Cell Cycle, 2006, 5, 242-245.	1.3	49

#	Article	IF	Citations
109	The development of systemic sclerosis classification criteria. Clinical Rheumatology, 2007, 26, 1401-1409.	1.0	48
110	Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects. Medicine (United States), 2016, 95, e4713.	0.4	48
111	Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. Arthritis Research and Therapy, 2020, 22, 5.	1.6	48
112	Detection of autoantibodies to ss-a/ro by indirect immunofluorescence using a transfected and overexpressed human 60 kd ro autoantigen in hep-2 cells. Journal of Clinical Laboratory Analysis, 1995, 9, 218-224.	0.9	47
113	Antibodies from patients with autoimmune disease react with a cytoplasmic antigen in the Golgi apparatus. Journal of Immunology, 1984, 132, 2904-8.	0.4	47
114	Autoantibodies in Childhood Post-Varicella Acute Cerebellar Ataxia. Canadian Journal of Neurological Sciences, 2000, 27, 316-320.	0.3	46
115	Anti-Scl-70 (topo-I) antibodies in SLE: Myth or reality?. Autoimmunity Reviews, 2010, 9, 756-760.	2.5	46
116	The clinical significance of autoantibodies to the proliferating cell nuclear antigen (PCNA). Autoimmunity Reviews, 2012, 11, 771-775.	2.5	46
117	Ultrastructural characterization of primary cilia in pathologically characterized human glioblastoma multiforme (GBM) tumors. BMC Clinical Pathology, 2014, 14, 40.	1.8	46
118	Systemic Sclerosis. Medicine (United States), 2010, 89, 159-165.	0.4	45
119	Anti-Fibrillarin Antibody in African American Patients with Systemic Sclerosis: Immunogenetics, Clinical Features, and Survival Analysis. Journal of Rheumatology, 2011, 38, 1622-1630.	1.0	45
120	Giantin is the major Golgi autoantigen in human anti-Golgi complex sera. Arthritis Research, 2004, 6, R95.	2.0	44
121	Diagnostic criteria of systemic sclerosis. Journal of Autoimmunity, 2014, 48-49, 38-41.	3.0	44
122	A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories. Journal of Rheumatology, 2003, 30, 2374-81.	1.0	44
123	Small Interfering RNA-mediated Silencing Induces Target-dependent Assembly of GW/P Bodies. Molecular Biology of the Cell, 2007, 18, 3375-3387.	0.9	42
124	Autoantibodies to GW bodies and other autoantigens in primary biliary cirrhosis. Clinical and Experimental Immunology, 2011, 163, 147-156.	1.1	42
125	Emerging technologies in autoantibody testing for rheumatic diseases. Arthritis Research and Therapy, 2017, 19, 172.	1.6	42
126	A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content. Journal of Rheumatology, 2002, 29, 68-74.	1.0	42

#	Article	IF	Citations
127	ASE-1: a novel protein of the fibrillar centres of the nucleolus and nucleolus organizer region of mitotic chromosomes. Chromosoma, 1997, 106, 493.	1.0	41
128	Unique and shared features of Golgi complex autoantigens. Autoimmunity Reviews, 2005, 4, 35-41.	2.5	39
129	Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients. Annals of the Rheumatic Diseases, 2021, 80, 1236-1240.	0.5	39
130	The centromere kinesin-like protein, CENP-E. An autoantigen in systemic sclerosis. Arthritis and Rheumatism, 1996, 39, 1355-1361.	6.7	38
131	Technical and clinical evaluation of anti-ribosomal P protein immunoassays. Journal of Clinical Laboratory Analysis, 2004, 18, 215-223.	0.9	38
132	Association of autoantibodies with Ku and DNA repair proteins in connective tissue diseases. Rheumatology, 2007, 47, 165-171.	0.9	38
133	Antibodies to Hmg Proteins in Patients with Drug-Induced Autoimmunity. Arthritis and Rheumatism, 1994, 37, 98-103.	6.7	37
134	Detection of autoantibodies using chemiluminescence technologies. Immunopharmacology and Immunotoxicology, 2016, 38, 14-20.	1.1	37
135	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Annals of the Rheumatic Diseases, 2021, 80, 775-781.	0.5	37
136	Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis. Frontiers in Immunology, 2019, 10, 745.	2.2	36
137	Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic. BMC Pulmonary Medicine, 2021, 21, 173.	0.8	36
138	A proposal of criteria for the classification of systemic sclerosis. Medical Science Monitor, 2004, 10, CR615-21.	0.5	36
139	Autoantigens of the nuclear pore complex. Journal of Molecular Medicine, 2004, 82, 423-33.	1.7	35
140	Anti-centromere antibodies in a large cohort of systemic sclerosis patients: Comparison between immunofluorescence, CENP-A and CENP-B ELISA. Clinica Chimica Acta, 2011, 412, 1937-1943.	0.5	35
141	Chronic smoke exposure induces rheumatoid factor and antiâ€heat shock protein 70 autoantibodies in susceptible mice and humans with lung disease. European Journal of Immunology, 2012, 42, 1051-1061.	1.6	35
142	Preventing the development of SLE: identifying risk factors and proposing pathways for clinical care. Lupus, 2016, 25, 838-849.	0.8	35
143	Improving Appropriate Access to Care With Central Referral and Triage in Rheumatology. Arthritis Care and Research, 2016, 68, 1547-1553.	1.5	35
144	Clinical relevance of autoantibodies in systemic rheumatic diseases. Molecular Biology Reports, 1996, 23, 133-145.	1.0	34

#	Article	IF	Citations
145	Autoantibodies in lupus nephritis patients requiring renal transplantation. Lupus, 2007, 16, 394-400.	0.8	34
146	Markers of mRNA stabilization and degradation, and RNAi within astrocytoma GW bodies. Journal of Neuroscience Research, 2007, 85, 3619-3631.	1.3	34
147	Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls. Journal of Rheumatology, 2015, 42, 2419-2426.	1.0	34
148	How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative. Immunologic Research, 2021, 69, 594-608.	1.3	34
149	Autoantibodies in Scleroderma. Journal of Dermatology, 1993, 20, 257-268.	0.6	33
150	The nuclear pore complex protein Tpr is a common autoantigen in sera that demonstrate nuclear envelope staining by indirect immunofluorescence. Clinical and Experimental Immunology, 2004, 136, 379-387.	1.1	33
151	Toward a new autoantibody diagnostic orthodoxy: understanding the bad, good and indifferent. Autoimmunity Highlights, 2012, 3, 51-58.	3.9	32
152	Human Autoantibodies to a Novel Golgi Protein Golgin-67: High Similarity With Golgin-95/gm 130 Autoantigen. Journal of Autoimmunity, 2000, 14, 179-187.	3.0	31
153	Synthetic Peptides: The Future of Patient Management in Systemic Rheumatic Diseases?. Current Medicinal Chemistry, 2007, 14, 2831-2838.	1.2	31
154	Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?. Annals of the Rheumatic Diseases, 2019, 78, e46-e46.	0.5	31
155	The International Consensus on ANA Patterns (ICAP) in 2021â€"The 6th Workshop and Current Perspectives. journal of applied laboratory medicine, The, 2022, 7, 322-330.	0.6	31
156	Immunocytochemical characterization of human NOR-90 (upstream binding factor) and associated antigens reactive with autoimmune sera. Molecular Biology Reports, 1994, 19, 115-124.	1.0	30
157	Specificity of autoantibodies to SS-A/Ro on a transfected and overexpressed human 60 kDa Ro autoantigen substrate. Journal of Clinical Laboratory Analysis, 2002, 16, 103-108.	0.9	30
158	Spectrum of centrosome autoantibodies in childhood varicella and post-varicella acute cerebellar ataxia. BMC Pediatrics, 2003, 3, 11.	0.7	30
159	A Panel of Monoclonal Antibodies to Cytoplasmic GW Bodies and the mRNA Binding Protein GW182. Hybridoma, 2003, 22, 79-86.	0.6	30
160	Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection. BMC Gastroenterology, 2013, 13, 50.	0.8	30
161	The Utilization of Autoantibodies in Approaches to Precision Health. Frontiers in Immunology, 2018, 9, 2682.	2.2	30
162	Early endosome antigen. 1: An autoantigen associated with neurological diseases. Journal of Investigative Medicine, 1999, 47, 311-8.	0.7	30

#	Article	IF	Citations
163	Thinking outside the boxâ€"The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect. Seminars in Arthritis and Rheumatism, 2015, 45, 184-189.	1.6	29
164	Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. Autoimmunity, 2015, 48, 542-551.	1.2	29
165	Progress in understanding the diagnostic and pathogenic role of autoantibodies associated with systemic sclerosis. Current Opinion in Rheumatology, 2016, 28, 586-594.	2.0	29
166	KSHV RNA-binding protein ORF57 inhibits P-body formation to promote viral multiplication by interaction with Ago2 and GW182. Nucleic Acids Research, 2019, 47, 9368-9385.	6.5	29
167	Antibodies to fibrin bound tissue type plasminogen activator in systemic sclerosis. Journal of Rheumatology, 1995, 22, 1688-93.	1.0	29
168	Urinary mercury levels in patients with autoantibodies to U3-RNP (fibrillarin). Journal of Rheumatology, 2000, 27, 405-10.	1.0	29
169	Identification of the B-cell epitopes of the early endosome antigen 1 (EEA1). Clinical Immunology, 2003, 109, 154-164.	1.4	28
170	Improved Serological Differentiation between Systemic Lupus Erythematosus and Mixed Connective Tissue Disease by Use of an SmD3 Peptide-Based Immunoassay. Vaccine Journal, 2005, 12, 107-113.	3.2	28
171	Anti-p97/VCP Antibodies: An Autoantibody Marker for a Subset of Primary Biliary Cirrhosis Patients with Milder Disease?. Scandinavian Journal of Immunology, 2006, 63, 376-382.	1.3	28
172	The Spectrum of Anti-Chromatin/Nucleosome Autoantibodies: Independent and Interdependent Biomarkers of Disease. Journal of Immunology Research, 2014, 2014, 1-15.	0.9	28
173	Absence of an association between anti-Ro antibodies and prolonged QTc interval in systemic sclerosis: A multicenter study of 689 patients. Seminars in Arthritis and Rheumatism, 2014, 44, 338-344.	1.6	28
174	Autoantibodies from primary biliary cirrhosis patients with anti-p95c antibodies bind to recombinant p97/VCP and inhibit in vitro nuclear envelope assembly. Clinical and Experimental Immunology, 2004, 136, 568-573.	1.1	27
175	The MicroRNA and MessengerRNA Profile of the RNA-Induced Silencing Complex in Human Primary Astrocyte and Astrocytoma Cells. PLoS ONE, 2010, 5, e13445.	1.1	27
176	Autoantibodies to the mitochondrial RNA processing (MRP) complex also known as Th/To autoantigen. Autoimmunity Reviews, 2015, 14, 254-257.	2.5	27
177	Autoantibodies in SLE: prediction and thepvalue matrix. Lupus, 2019, 28, 1285-1293.	0.8	27
178	Antibodies to high mobility group proteins in systemic sclerosis. Journal of Rheumatology, 1994, 21, 2071-5.	1.0	27
179	Diversity and origin of rheumatologic autoantibodies. Clinical Microbiology Reviews, 1991, 4, 256-269.	5.7	26
180	Anti-dsDNA antibody testing in the clinic: Farr or ELISA?. Nature Clinical Practice Rheumatology, 2007, 3, 72-73.	3.2	26

#	Article	IF	Citations
181	International Consensus on Antinuclear Antibody Patterns: defining negative results and reporting unidentified patterns. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1799-1802.	1.4	26
182	Prolonged improvement of raynaud's phenomenon and scleroderma after recombinant tissue plasminogen activator therapy. Arthritis and Rheumatism, 1990, 33, 274-276.	6.7	25
183	The cytoplasmic linker protein CLIP-170 is a human autoantigen. Clinical and Experimental Immunology, 2002, 127, 533-538.	1.1	25
184	Relationship of Other Cytoplasmic Ribonucleoprotein Bodies (cRNPB) to GW/P Bodies. Advances in Experimental Medicine and Biology, 2013, 768, 213-242.	0.8	25
185	Mammalian microtubule P-body dynamics are mediated by nesprin-1. Journal of Cell Biology, 2014, 205, 457-475.	2.3	25
186	Antifibrillarin Antibodies Are Associated with Native North American Ethnicity and Poorer Survival in Systemic Sclerosis. Journal of Rheumatology, 2017, 44, 799-805.	1.0	25
187	Describing and expanding the clinical phenotype of anti-MDA5-associated rapidly progressive interstitial lung disease: case series of nine Canadian patients and literature review. Scandinavian Journal of Rheumatology, 2018, 47, 210-224.	0.6	25
188	Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets. Autoimmunity Reviews, 2020, 19, 102583.	2.5	25
189	Anti-mitochondrial autoantibodies. Clinical and Applied Immunology Reviews, 2002, 3, 87-113.	0.4	24
190	Microbead-based technologies in diagnostic autoantibody detection. Expert Opinion on Medical Diagnostics, 2009, 3, 81-89.	1.6	24
191	Optimization of immunoprecipitationâ€“western blot analysis in detecting GW182-associated components of GW/P bodies. Nature Protocols, 2009, 4, 674-685.	5.5	24
192	Rpp25 is a major target of autoantibodies to the Th/To complex as measured by a novel chemiluminescent assay. Arthritis Research and Therapy, 2013, 15, R50.	1.6	24
193	Detection of myositis-specific antibodies: additional notes. Annals of the Rheumatic Diseases, 2019, 78, e45-e45.	0.5	24
194	Validity Evidence for the Use of Automated Neuropsychologic Assessment Metrics As a Screening Tool for Cognitive Impairment in Systemic Lupus Erythematosus. Arthritis Care and Research, 2020, 72, 1809-1819.	1.5	24
195	Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. Clinical and Experimental Rheumatology, 2015, 33, S131-5.	0.4	24
196	Clinical and serological evaluation of a novel CENP-A peptide based ELISA. Arthritis Research and Therapy, 2010, 12, R99.	1.6	23
197	Prevalence of Systemic Sclerosis in Primary Biliary Cholangitis Using the New ACR/EULAR Classification Criteria. Journal of Rheumatology, 2017, 44, 33-39.	1.0	23
198	Harmonization of clinical interpretation of antinuclear antibody test results by solid phase assay and by indirect immunofluorescence through likelihood ratios. Autoimmunity Reviews, 2019, 18, 102386.	2.5	23

#	Article	IF	Citations
199	Long-term exposure to a mixture of industrial SO2, NO2, and PM2.5 and anti-citrullinated protein antibody positivity. Environmental Health, 2020, 19, 86.	1.7	23
200	Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies. RMD Open, 2020, 6, e001357.	1.8	23
201	Precision health: A pragmatic approach to understanding and addressing key factors in autoimmune diseases. Autoimmunity Reviews, 2020, 19, 102508.	2.5	23
202	Identification of a subset of patients with scleroderma with severe pulmonary and vascular disease by the presence of autoantibodies to centromere and histone.. Annals of the Rheumatic Diseases, 1993, 52, 780-784.	0.5	22
203	Major immunoreactive domains of human ribosomal P proteins lie N-terminal to a homologous C-22 sequence: application to a novel ELISA for systemic lupus erythematosus. Clinical and Experimental Immunology, 2005, 141, 155-164.	1.1	22
204	PM1-Alpha ELISA: The assay of choice for the detection of anti-PM/Scl autoantibodies?. Autoimmunity Reviews, 2009, 8, 373-378.	2.5	22
205	Novel diagnostic and clinical aspects of anti-PCNA antibodies detected by novel detection methods. Lupus, 2010, 19, 1527-1533.	0.8	22
206	Autoantibodies to the Rpp25 Component of the Th/To Complex are the Most Common Antibodies in Patients with Systemic Sclerosis without Antibodies Detectable by Widely Available Commercial Tests. Journal of Rheumatology, 2014, 41, 1334-1343.	1.0	22
207	Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS). PLoS ONE, 2018, 13, e0193960.	1.1	22
208	High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F. Clinical and Investigative Medicine, 1997, 20, 308-19.	0.3	22
209	The Prevalence of Anti-Hexokinase-1 and Anti-Kelch-Like 12 Peptide Antibodies in Patients With Primary Biliary Cholangitis Is Similar in Europe and North America: A Large International, Multi-Center Study. Frontiers in Immunology, 2019, 10, 662.	2.2	21
210	Antinuclear antibodies by indirect immunofluorescence and solid phase assays. Annals of the Rheumatic Diseases, 2020, 79, e65-e65.	0.5	21
211	Repression of GW/P body components and the RNAi microprocessor impacts primary ciliogenesis in human astrocytes. BMC Cell Biology, 2011, 12, 37.	3.0	20
212	Autoantibodies to Mi-2 alpha and Mi-2 beta in patients with idiopathic inflammatory myopathy. Rheumatology, 2019, 58, 1655-1661.	0.9	20
213	Investigating associations between anti-nuclear antibody positivity and combined long-term exposures to NO2, O3, and PM2.5 using a Bayesian kernel machine regression approach. Environment International, 2020, 136, 105472.	4.8	20
214	Autoantibodies to components of the mitotic apparatus. Molecular Biology Reports, 1998, 25, 143-155.	1.0	19
215	The changing landscape of the clinical value of the PM/Scl autoantibody system. Arthritis Research and Therapy, 2009, 11, 106.	1.6	19
216	The Antinuclear Antibody Test in the Diagnosis of Antisynthetase Syndrome and Other Autoimmune Myopathies. Journal of Rheumatology, 2018, 45, 444.1-445.	1.0	19

#	Article	IF	Citations
217	Bicaudal D2 is a novel autoantibody target in systemic sclerosis that shares a key epitope with CENP-A but has a distinct clinical phenotype. Autoimmunity Reviews, 2018, 17, 267-275.	2.5	19
218	Golgins: coiled-coil-rich proteins associated with the Golgi Complex. Electronic Journal of Biotechnology, 1998, 1, 45-54.	1.2	19
219	Autoantibody testing: procedures and significance in systemic rheumatic diseases. Methods and Achievements in Experimental Pathology, 1986, 12, 224-60.	0.3	19
220	T Lymphocytes from Hemophiliacs Proliferate after Exposure to Factor VIII Product. Vox Sanguinis, 1986, 51, 92-95.	0.7	18
221	Autoantibodies to early endosome antigen (EEA1) produce a staining pattern resembling cytoplasmic anti-neutrophil cytoplasmic antibodies (C-ANCA). Clinical and Experimental Immunology, 2000, 122, 493-498.	1.1	18
222	Human autoantibodies to diacyl-phosphatidylethanolamine recognize a specific set of discrete cytoplasmic domains. Clinical and Experimental Immunology, 2006, 143, 572-584.	1.1	18
223	Development and multi-center evaluation of a novel immunoadsorption method for anti-DFS70 antibodies. Lupus, 2016, 25, 897-904.	0.8	18
224	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. Arthritis Research and Therapy, 2016, 18, 20.	1.6	18
225	Reference standards for the detection of anti-mitochondrial and anti-rods/rings autoantibodies. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1789-1798.	1.4	18
226	Human autoantibodies against early endosome antigen-1 enhance excitatory synaptic transmission. Neuroscience, 2006, 143, 953-964.	1.1	17
227	Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope. Rheumatology International, 2012, 32, 691-698.	1.5	17
228	Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?. Nature Reviews Rheumatology, 2014, 10, 682-690.	3.5	17
229	COVID-19-associated autoimmunity as a feature of acute respiratory failure. Intensive Care Medicine, 2021, 47, 801-804.	3.9	17
230	Histopathological features of systemic sclerosis-associated myopathy: A scoping review. Autoimmunity Reviews, 2021, 20, 102851.	2.5	17
231	Establishment of an international autoantibody reference standard for human anti-DFS70 antibodies: proof-of-concept study for a novel Megapool strategy by pooling individual specific sera. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1754-1763.	1.4	16
232	Autoantibody profiles delineate distinct subsets of scleromyositis. Rheumatology, 2022, 61, 1148-1157.	0.9	16
233	Expression of a constitutively active humanSTINGmutant in hematopoietic cells produces anIfnar1-dependent vasculopathy in mice. Life Science Alliance, 2019, 2, e201800215.	1.3	16
234	Antinuclear antibodies (ANA) as a criterion for classification and diagnosis of systemic autoimmune diseases. Journal of Translational Autoimmunity, 2022, 5, 100145.	2.0	16

#	Article	IF	Citations
235	Analysis of human sera that are polyreactive in an addressable laser bead immunoassay. Clinical Immunology, 2006, 120, 349-356.	1.4	15
236	Challenges and Controversies in Autoantibodies Associated with Systemic Rheumatic Diseases. Current Rheumatology Reviews, 2007, 3, 67-78.	0.4	15
237	Systemic Sclerosis Immunoglobulin Induces Growth and a Pro-Fibrotic State in Vascular Smooth Muscle Cells through the Epidermal Growth Factor Receptor. PLoS ONE, 2014, 9, e100035.	1.1	15
238	Autoantibodies from patients with idiopathic ataxia bind to M-phase phosphoprotein-1 (MPP1). Journal of Investigative Medicine, 2000, 48, 28-39.	0.7	15
239	Advances in autoantibodies in SLE. Lupus, 1998, 7, 507-514.	0.8	14
240	Autoantibodies to the survival of motor neuron complex in a patient with necrotizing autoimmune myopathy. Rheumatology, 2018, 57, 199-200.	0.9	14
241	Redefining systemic lupus erythematosus â€" SMAARTT proteomics. Nature Reviews Rheumatology, 2018, 14, 451-452.	3.5	14
242	Rheumatoid arthritis-relevant DNA methylation changes identified in ACPA-positive asymptomatic individuals using methylome capture sequencing. Clinical Epigenetics, 2019, 11, 110.	1.8	14
243	Altered neurological function in mice immunized with early endosome antigen 1. BMC Neuroscience, 2004, 5, 2.	0.8	13
244	Identification of GRASP-1 as a novel 97 kDa autoantigen localized to endosomes. Clinical Immunology, 2005, 116, 108-117.	1.4	13
245	Autoantibodies in Systemic Autoimmune Disorders. Journal of Immunology Research, 2014, 2014, 1-2.	0.9	13
246	Autoantibody Discovery, Assay Development and Adoption: Death Valley, the Sea of Survival and Beyond. Frontiers in Immunology, 2021, 12, 679613.	2.2	13
247	<scp>COVID</scp>â€19â€Associated Critical Illness Myopathy with Direct Viral Effects. Annals of Neurology, 2022, 91, 568-574.	2.8	13
248	The Effect of <scp>Antiâ€Scl</scp>â€70 Antibody Determination Method on Its Predictive Significance for Interstitial Lung Disease Progression in Systemic Sclerosis. ACR Open Rheumatology, 2022, 4, 345-351.	0.9	12
249	Diverse humoral autoimmunity to the ribosomal P proteins in systemic lupus erythematosus and hepatitis C virus infection. Journal of Molecular Medicine, 2007, 85, 953-959.	1.7	11
250	An Autoimmune Myositis-Overlap Syndrome Associated With Autoantibodies to Nuclear Pore Complexes. Medicine (United States), 2014, 93, 383-394.	0.4	11
251	Subsets in systemic sclerosis: one size does not fit all. Journal of Scleroderma and Related Disorders, 2016, 1, 298-306.	1.0	11
252	Clinical and serological associations of autoantibodies to the Ku70/Ku80 heterodimer determined by a novel chemiluminescent immunoassay. Lupus, 2016, 25, 889-896.	0.8	11

#	Article	IF	Citations
253	Analysis of autoantibody profiles in two asbestiform fiber exposure cohorts. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2018, 81, 1015-1027.	1.1	11
254	Longitudinal relationships between cognitive domains and depression and anxiety symptoms in systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 2021, 51, 1186-1192.	1.6	11
255	Association between autoantibodies in systemic sclerosis and cancer in a national registry. Rheumatology, 2022, 61, 2905-2914.	0.9	11
256	Assessment of antinuclear antibodies by indirect immunofluorescence assay: report from a survey by the American Association of Medical Laboratory Immunologists. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1489-1497.	1.4	11
257	Immuneâ€mediated necrotizing myopathy after <scp>BNT162b2</scp> vaccination in a patient with antibodies against receptorâ€binding domain of <scp>SARSâ€CoV</scp>â€2 and signal recognition particle. Muscle and Nerve, 2022, 65, .	1.0	11
258	Development and validation of a lateral flow assay (LFA) for the determination of IgG-antibodies to Pr3 (cANCA) and MPO (pANCA). Journal of Immunological Methods, 2014, 403, 1-6.	0.6	10
259	Scurfy Mice Develop Features of Connective Tissue Disease Overlap Syndrome and Mixed Connective Tissue Disease in the Absence of Regulatory T Cells. Frontiers in Immunology, 2019, 10, 881.	2.2	10
260	Implications for redefining the dense fine speckled and related indirect immunofluorescence patterns. Expert Review of Clinical Immunology, 2019, 15, 447-448.	1.3	10
261	A case of aggressive atypical anti-GBM disease complicated by CMV pneumonitis. BMC Nephrology, 2019, 20, 29.	0.8	10
262	Myositis in systemic lupus erythematosus. Lupus, 2021, 30, 615-619.	0.8	10
263	Metrics and definitions used in the assessment of cognitive impairment in systemic lupus erythematosus: A systematic review. Seminars in Arthritis and Rheumatism, 2021, 51, 819-830.	1.6	10
264	Phospholipid-binding proteins differ in their capacity to induce autoantibodies and murine systemic lupus erythematosus. Lupus, 2014, 23, 752-768.	0.8	9
265	Challenges and Advances in SLE Autoantibody Detection and Interpretation. Current Treatment Options in Rheumatology, 2019, 5, 147-167.	0.6	9
266	N-Formyl Methionine Peptide-Mediated Neutrophil Activation in Systemic Sclerosis. Frontiers in Immunology, 2021, 12, 785275.	2.2	9
267	Autoantibodies to the nucleolar organizer antigen NOR-90 in children with systemic rheumatic diseases. Journal of Rheumatology, 1995, 22, 521-4.	1.0	9
268	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2022, 81, 1143-1150.	0.5	9
269	Autoantibodies: diagnostic fingerprints and etiologic perplexities. Clinical and Investigative Medicine, 1997, 20, 50-66.	0.3	8
270	Prevalence and titres of antinuclear antibodies in juvenile idiopathic arthritis: A systematic review and meta-analysis. Autoimmunity Reviews, 2022, 21, 103086.	2.5	8

#	Article	IF	Citations
271	Characterization of early endosome antigen 1 in neural tissues. Biochemical and Biophysical Research Communications, 2004, 323, 1334-1342.	1.0	7
272	The Discovery of GW Bodies. Advances in Experimental Medicine and Biology, 2013, 768, 5-21.	0.8	7
273	Antinuclear Antibodies in Children. Journal of Rheumatology, 2014, 41, 1260-1262.	1.0	7
274	Autoantibody status is not associated with change in lung function or survival in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 153, 85-90.	1.3	7
275	The antinuclear antibody HEp-2 indirect immunofluorescence assay: a survey of laboratory performance, pattern recognition and interpretation. Autoimmunity Highlights, 2021, 12, 4.	3.9	7
276	Normal anti-Klebsiella lymphocytotoxicity in ankylosing spondylitis. Arthritis and Rheumatism, 1986, 29, 358-362.	6.7	6
277	A case of limited cutaneous systemic sclerosis developing anti-mitochondria antibody positive primary biliary cirrhosis after acute myocardial infarction. Clinical Rheumatology, 2007, 26, 1571-1574.	1.0	6
278	Autoantibody Assays, Testing, and Standardization. , 2006, , 1011-1022.		6
279	The relationship of ASE-1 and NOR-90 in autoimmune sera. Journal of Rheumatology, 1998, 25, 2126-30.	1.0	6
280	Reduced skin threshold to irritation in the presence of allergic contact dermatitis in the guinea pig. Contact Dermatitis, 1984, 11, 31-33.	0.8	5
281	The Safety and Efficacy of Lowâ€dose Tissue Plasminogen Activator in the Treatment of Systemic Sclerosis. Journal of Dermatology, 1995, 22, 637-642.	0.6	5
282	Clinical and Serological Analysis of Patients with Positive Anticyclic Citrullinated Peptide Antibodies Referred Through a Rheumatology Central Triage System. Journal of Rheumatology, 2015, 42, 771-777.	1.0	5
283	Editorial: Are Autoantibodies Involved in the Pathogenesis of Systemic Sclerosis?. Arthritis and Rheumatology, 2016, 68, 2067-2070.	2.9	5
284	A Monoclonal Antibody to M-Phase Phosphoprotein 1/Kinesin-Like Protein KIF20B. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2019, 38, 162-170.	0.8	5
285	Comment on: The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity. Rheumatology, 2021, 60, e35-e37.	0.9	5
286	Evaluation of a novel particle-based multi-analyte technology for the detection of anti-fibrillarin antibodies. Immunologic Research, 2021, 69, 239-248.	1.3	5
287	Centriole and Centrosome Autoantibodies. , 1996, , 153-160.		5
288	Antinuclear Antibody Testing: Gold Standard Revisited. journal of applied laboratory medicine, The, 2022, 7, 357-361.	0.6	5

#	Article	IF	Citations
289	Antihistone and Antispliceosomal Antibodies. , 2011, , 275-292.		4
290	Reflections on Ten Years of History of, and Future Prospects for, GW182 and GW/P Body Research. Advances in Experimental Medicine and Biology, 2013, 768, 261-270.	0.8	4
291	Professional Insights from a Pioneer in Autoimmune Disease Testing: The Future of Antinuclear/Anticellular Antibody Testing. journal of applied laboratory medicine, The, 2019, 4, 287-289.	0.6	4
292	Anti-HMGCR antibodies in systemic sclerosis. Medicine (United States), 2016, 95, e5280.	0.4	4
293	Establishment of international autoantibody reference standards for the detection of autoantibodies directed against PML bodies, GW bodies, and NuMA protein. Clinical Chemistry and Laboratory Medicine, 2021, 59, 197-207.	1.4	4
294	Gene Expression Profiles of Treatment Response and <scp>Nonâ€Response</scp> in Children With Juvenile Dermatomyositis. ACR Open Rheumatology, 2022, 4, 671-681.	0.9	4
295	Advances in understanding newer autoantibodies and their role as biomarkers in systemic lupus erythematosus. Expert Opinion on Medical Diagnostics, 2007, 1, 393-408.	1.6	3
296	Diagnostic Utility of Anticarbamylated Protein Antibodies as Measured Using Carbamylated Fetal Calf Serum. Journal of Rheumatology, 2018, 45, 438-439.	1.0	3
297	Autoantibodies to a novel Rpp38 (Th/To) derived B-cell epitope are specific for systemic sclerosis and associate with a distinct clinical phenotype. Rheumatology, 2019, 58, 1784-1793.	0.9	3
298	Autoantibodies to a group of centrosomal proteins in human autoimmune sera reactive with the centrosome. , 1998, 41, 551.		3
299	The Role of Autoantibody Testing in Modern Personalized Medicine. Clinical Reviews in Allergy and Immunology, 2022, 63, 251-288.	2.9	3
300	Comment on: Concordance between myositis autoantibodies and anti-nuclear antibody patterns in a real-world, Australian cohort. Rheumatology, 2022, 61, e290-e291.	0.9	3
301	Validation of the automated neuropsychological assessment metrics for assessing cognitive impairment in systemic lupus erythematosus. Lupus, 2022, 31, 45-54.	0.8	3
302	GW Bodies: Cytoplasmic Compartments in Normal Human Skin. Journal of Investigative Dermatology, 2008, 128, 2909-2912.	0.3	2
303	An SNP in the Trinucleotide Repeat Region of the TNRC6A Gene Maps to a Major TNGW1 Autoepitope in Patients with Autoantibodies to GW182. Advances in Experimental Medicine and Biology, 2013, 768, 243-259.	0.8	2
304	Reflections on Lupus 2013: butterflies, wolves and prophecies. Lupus, 2013, 22, 1092-1101.	0.8	2
305	Commentary on the recent international multicentre study (EUVAS) on antineutrophil cytoplasmic antibodies. Annals of the Rheumatic Diseases, 2017, 76, e38-e38.	0.5	2
306	Sunlight exposure, sunâ€protective behaviour, and antiâ€citrullinated protein antibody positivity: A general populationâ€based study in Quebec, Canada. Arthritis Care and Research, 2020, , .	1.5	2

#	Article	IF	Citations
307	Development of multi-omics approach in autoimmune diseases. , 2021, , 189-201.		2
308	Do anti-DFS70 antibodies temper disease activity and progression in SLE?. Lupus, 2021, 30, 852-853.	0.8	2
309	Thousands of CpGs Show DNA Methylation Differences in ACPA-Positive Individuals. Genes, 2021, 12, 1349.	1.0	2
310	Precision medicine as an approach to autoimmune diseases. , 2021, , 39-63.		2
311	Advances in understanding and use of autoantibodies as markers of diseases. , 2003, , 29-42.		2
312	Relationship between calcium channel blockers and skin fibrosis in patients with systemic sclerosis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 56-60.	0.4	2
313	SARS-CoV-2 seroprevalence, seroconversion and neutralizing antibodies in a systemic lupus erythematosus cohort and comparison to controls. Lupus, 2021, 30, 2318-2320.	0.8	2
314	Significance of Autoantibodies to Ki/SL as Biomarkers for Systemic Lupus Erythematosus and Sicca Syndrome. Journal of Clinical Medicine, 2022, 11, 3529.	1.0	2
315	GOLGI COMPLEX AND ENDOSOME ANTIBODIES. , 2007, , 263-270.		1
316	Autoantibodies to GW/P Bodies and Components of the MicroRNA Pathway. , 2014, , 257-263.		1
317	Antiâ€Th/To Antibodies: Association With Lung Disease and Potential Protection From Systemic Sclerosisâ€"Related Cancer? Comment on the Article by Mecoli et al. Arthritis and Rheumatology, 2021, 73, 545-546.	2.9	1
318	Challenges and Advances in SLE Autoantibody Detection and Interpretation. , 2021, , 67-91.		1
319	Autoantibodies and cancer among asbestos-exposed cohorts in Western Australia. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2021, 84, 475-483.	1.1	1
320	ANTIBODIES TO NONHISTONE ANTIGENS IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 2004, , 349-376.		1
321	Detection of Autoantibodies by Enzyme-Linked Immunosorbent Assay and Bead Assays. , 0, , 859-867.		1
322	OUP accepted manuscript. journal of applied laboratory medicine, The, 2022, 7, 362-366.	0.6	1
323	Anti-synthetase syndrome occurring after SARS-CoV-2 infection. Scandinavian Journal of Rheumatology, 2022, 51, 255-257.	0.6	1
324	Myositis with prominent B-cell aggregates causing shrinking lung syndrome in systemic lupus erythematosus: a case report. BMC Rheumatology, 2022, 6, 11.	0.6	1

#	Article	IF	Citations
325	A Review on Biomarkers for the Evaluation of Autoimmune Cholestatic Liver Diseases and Their Overlap Syndromes. Frontiers in Molecular Medicine, 0, 2, .	0.6	1
326	GW BODIES, P BODIES AND COMPONENTS OF THE miRNA PATHWAY. , 2007, , 257-262.		0
327	Golgi Complex and Endosome Antibodies. , 2014, , 265-273.		0
328	Antinucleolar Antibodies as Diagnostic Markers in Systemic Autoimmune Diseases. , 2014, , 145-150.		0
329	Autoantibody Assays. , 2014, , 1161-1175.		0
330	Antiâ€early endosome antigen 1 autoantibodies were detected in a pemphigusâ€like patient but not in the majority of pemphigus diseases. Experimental Dermatology, 2016, 25, 368-374.	1.4	0
331	Autoantibodies directed to centromere protein F in a patient with BRCA1 gene mutation. BMC Research Notes, 2016, 9, 84.	0.6	0
332	Dr Eng M. Tan: a tribute to an enduring legacy in autoimmunity. Lupus, 2017, 26, 208-217.	0.8	0
333	Autoantibodies to mRNA processing pathways (glycine and tryptophan-rich bodies antibodies): prevalence and clinical utility in a South Australian cohort. Pathology, 2019, 51, 723-726.	0.3	0
334	Autoantibody Assays: Performance, Interpretation, and Standardization. , 2020, , 1369-1389.		0
335	Reply. Arthritis Care and Research, 2020, 72, 734-735.	1.5	0
336	Checkpoint inhibitors: Interface of cancer and autoimmunity: Opportunity for second level precision medicine. , 2021, , 109-134.		0
337	Trigeminal neuralgia in systemic sclerosis. Seminars in Arthritis and Rheumatism, 2021, 51, 318-323.	1.6	0
338	High intelligence may exacerbate paediatric inflammatory response to SARS-CoV-2 infection. Medical Hypotheses, 2021, 155, 110677.	0.8	0
339	Systemic Sclerosis. , 2008, , 31-36.		0
340	Type I IFNâ€mediated Inhibition of Inflammatory Th cell Responses by a Subset of SLE Patient Sera. FASEB Journal, 2008, 22, 669.16.	0.2	0
341	1704â€…Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
342	Response to: Correspondence on â€˜Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patientsâ€™ by Liu. Annals of the Rheumatic Diseases, 2023, 82, e180-e180.	0.5	0

#	Article	IF	Citations
343	Antiphospholipid Antibody Profiles and Thrombotic Outcomes in the Starlet Cohort of Patients with Systemic Lupus Erythematosus. Blood, 2021, 138, 2126-2126.	0.6	0
344	Cytokine autoantibodies in SARS-CoV-2 prepandemic and intrapandemic samples from an SLE cohort. Lupus Science and Medicine, 2022, 9, e000667.	1.1	0